Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Toxicol Pathol ; 47(3): 250-263, 2019 04.
Article in English | MEDLINE | ID: mdl-30599801

ABSTRACT

Thorough morphologic evaluations of medical devices placed in or near the nervous system depend on many factors. Pathologists interpreting a neurologic device study must be familiar with the regulatory framework affecting device development, biocompatibility and safety determinants impacting nervous tissue responses, and appropriate study design, including the use of appropriate animal models, group design, device localization, euthanasia time points, tissue examination, sampling and processing, histochemistry and immunohistochemistry, and reporting. This overview contextualizes these features of neurologic medical devices for pathologists engaged in device evaluations.


Subject(s)
Equipment Design/standards , Equipment Safety/standards , Equipment and Supplies/standards , Nervous System/pathology , Pathologists , Animals , Biocompatible Materials/standards , Humans , Materials Testing/methods , Medical Device Legislation
2.
Toxicol Pathol ; 47(3): 201-202, 2019 04.
Article in English | MEDLINE | ID: mdl-30585129

ABSTRACT

Medical devices comprise a wide variety of therapeutic tools aimed at modulating or restoring organ function. Devices may be implanted or activated temporally or permanently, and are used to deliver a wide range of therapies such as drugs, electrical stimulation, laser, thermal energy, offer mechanical support, and restore sensory functions. Technological advancements allow improvement and development of devices at a rapid pace. This special issue of Toxicologic Pathology addresses a need for more publications focused on pathology evaluation of medical devices in preclinical studies and highlights fundamental approaches through practical examples bringing into perspective the essential role of pathologists in this field.


Subject(s)
Biocompatible Materials/adverse effects , Equipment Safety , Equipment and Supplies/adverse effects , Pathology/methods , Animals , Biocompatible Materials/standards , Equipment and Supplies/standards , Humans , Materials Testing/methods , Materials Testing/standards , Pathology/standards
3.
J Neurosurg Spine ; 25(2): 154-64, 2016 Aug.
Article in English | MEDLINE | ID: mdl-26989976

ABSTRACT

OBJECTIVE It has been hypothesized that the recombinant human bone morphogenetic protein-2 (rhBMP-2) amplification of the host inflammatory response interacts with nerves in the spine and contributes to the occurrence of new, postoperative complaints of radiculitis. This in vivo rat study was conducted to assess the capacity for rhBMP-2/ACS (rhBMP-2 applied to absorbable collagen sponge [ACS]) to stimulate pain-associated behaviors in the rat chronic constriction injury (CCI) model. METHODS Rats were randomly assigned to one of 14 treatment groups. Half of the animals underwent a sham procedure in which the left sciatic nerve was exposed and manipulated but no ligature was placed (Sham cohort), while the remaining animals had chromic gut sutures tied around the sciatic nerve to induce CCI (CCI cohort). The following test articles were applied to the sciatic nerve in each cohort: saline alone, saline applied to ACS, 0.1 mg/ml rhBMP-2 applied to ACS, or 1.0 mg/ml rhBMP-2 applied to ACS. The ACS was either wrapped around the sciatic nerve or implanted adjacent to the nerve. Thermal withdrawal latency was assessed on Days 7, 14, 21, and 28 postoperatively. Isolated nerves from selected rats in each group were examined and assessed for histopathological changes on Days 3, 7, 14, and 28. RESULTS CCI produced a significant pain behavioral response for all treatment groups at all time points. In the Sham cohort, 0.1 mg/ml rhBMP-2/ACS wrapped around the nerve (WRP) decreased thermal withdrawal on Day 28, and 1.0 mg/ml rhBMP-2/ACS placed adjacent to the nerve (ADJ) decreased thermal withdrawal on Days 21 and 28. Conversely, in the CCI cohort, 0.1 mg/ml rhBMP-2/ACS ADJ increased thermal withdrawal latencies on Day 7; 1.0 mg/ml rhBMP-2/ACS ADJ increased thermal withdrawal latencies on Day 7; and 1.0 mg/ml rhBMP-2/ACS WRP increased thermal withdrawal on Days 7 and 14. Histologically, the effect of rhBMP-2 on nerve inflammation was unclear, as inflammatory cell infiltration was similar in the rhBMP-2/ACS and saline/ACS groups. rhBMP-2 was variably associated with bone formation within the epineurium at 14 days, and more prevalently at 28 days, with no clear relationship between dose or ACS positioning. CONCLUSIONS In this study, rhBMP-2/ACS did not appear to induce pain independent of grossly visible ectopic bone formation. At the earliest time points, rhBMP-2 appeared to have a neuroprotective effect as evidenced by decreased pain exhibited by the rhBMP-2-treated animals in the CCI cohort, but this effect diminished over time, and by Day 28, the pain behavioral responses in the rhBMP-2-treated group were comparable to those in the group in which saline was applied to the nerve. In the Sham cohort, there was a dose-independent induction of pain at later time points, presumably due to new bone formation mechanically irritating the nerve. Histological examination revealed nerve lesions that appeared to be caused by mechanical trauma associated with surgical manipulation of the nerve during placement of the ACS and/or CCI sutures.


Subject(s)
Bone Morphogenetic Protein 2/administration & dosage , Constriction, Pathologic/drug therapy , Motor Activity/drug effects , Osteogenesis/drug effects , Pain/physiopathology , Sciatic Nerve/drug effects , Sciatic Neuropathy/drug therapy , Transforming Growth Factor beta/administration & dosage , Absorbable Implants , Animals , Bone Morphogenetic Protein 2/adverse effects , Chronic Disease , Collagen , Constriction, Pathologic/pathology , Constriction, Pathologic/physiopathology , Constriction, Pathologic/surgery , Disease Models, Animal , Drug Implants , Hot Temperature , Hyperalgesia/etiology , Hyperalgesia/pathology , Hyperalgesia/physiopathology , Male , Pain/etiology , Pain/pathology , Pain Measurement , Random Allocation , Rats, Sprague-Dawley , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Sciatic Nerve/pathology , Sciatic Neuropathy/pathology , Sciatic Neuropathy/physiopathology , Sciatic Neuropathy/surgery , Transforming Growth Factor beta/adverse effects
4.
Am J Physiol Lung Cell Mol Physiol ; 308(5): L485-93, 2015 Mar 01.
Article in English | MEDLINE | ID: mdl-25575514

ABSTRACT

CD38 is a cell-surface protein involved in calcium signaling and contractility of airway smooth muscle. It has a role in normal airway responsiveness and in airway hyperresponsiveness (AHR) developed following airway exposure to IL-13 and TNF-α but appears not to be critical to airway inflammation in response to the cytokines. CD38 is also involved in T cell-mediated immune response to protein antigens. In this study, we assessed the contribution of CD38 to AHR and inflammation to two distinct allergens, ovalbumin and the epidemiologically relevant environmental fungus Alternaria. We also generated bone marrow chimeras to assess whether Cd38(+/+) inflammatory cells would restore AHR in the CD38-deficient (Cd38(-/-)) hosts following ovalbumin challenge. Results show that wild-type (WT) mice develop greater AHR to inhaled methacholine than Cd38(-/-) mice following challenge with either allergen, with comparable airway inflammation. Reciprocal bone marrow transfers did not change the native airway phenotypic differences between WT and Cd38(-/-) mice, indicating that the lower airway reactivity of Cd38(-/-) mice stems from Cd38(-/-) lung parenchymal cells. Following bone marrow transfer from either source and ovalbumin challenge, the phenotype of Cd38(-/-) hosts was partially reversed, whereas the airway phenotype of the WT hosts was preserved. Airway inflammation was similar in Cd38(-/-) and WT chimeras. These results indicate that loss of CD38 on hematopoietic cells is not sufficient to prevent AHR and that the magnitude of airway inflammation is not the predominant underlying determinant of AHR in mice.


Subject(s)
ADP-ribosyl Cyclase 1/deficiency , Bone Marrow Transplantation , Bronchial Hyperreactivity/pathology , Bronchial Hyperreactivity/therapy , Chimera/immunology , Respiratory Hypersensitivity/pathology , Respiratory Hypersensitivity/therapy , ADP-ribosyl Cyclase 1/metabolism , Administration, Inhalation , Allergens/immunology , Animals , Bone Marrow/metabolism , Bronchial Hyperreactivity/complications , Bronchoalveolar Lavage Fluid/cytology , Cell Count , Chemokines/metabolism , Lung/pathology , Lung/physiopathology , Methacholine Chloride/administration & dosage , Mice, Inbred C57BL , Ovalbumin/immunology , Pneumonia/complications , Pneumonia/pathology , Respiratory Hypersensitivity/complications
5.
J Cardiovasc Electrophysiol ; 24(8): 919-25, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23672309

ABSTRACT

INTRODUCTION: A novel cryoballoon with improved refrigerant distribution promises better pulmonary vein (PV) isolation success rate without sacrificing the technology's safety profile. This study aimed to compare the Arctic Front® (AF) balloon to the new Arctic Front Advance™ (AFA). METHODS AND RESULTS: Twenty pulmonary PVs from 10 healthy dogs weighing 29.8 ± 1.1 kg were assigned to ablation with AF and AFA, using a 23 mm or 28 mm balloon. A single 4-minute ablation was performed in each vessel, with no phrenic nerve monitoring. The Achieve™ mapping catheter was used to confirm acute isolation. Thirty days post-treatment the ablation sites were assessed for electrical PV isolation and ablation completeness via gross and histological examination. The phrenic nerve, PVs, lungs, esophagus, kidneys, and brain were collected for evaluation of potential damage. A preprocedural and prenecropsy CT were performed to assess incidence of PV stenosis. All 10 PVs were fully isolated with AFA; 6 of 10 PVs were fully isolated with AF. In all cases, lesion gaps with AF are believed to stem from inadequate cooling of the most distal balloon segment that was in contact with the unablated PV tissue. No untoward findings were detected on gross examination of the heart, esophagus, kidneys, brain, or PVs. One phrenic nerve had cross-sectional ablation associated with an AFA 23 mm balloon. Superficial regions of subpleural lung fibrosis were noted adjacent to 7 PVs. CONCLUSIONS: PV isolation and lesion completeness were improved with Arctic Front Advance, while no unexpected findings were found related to safety.


Subject(s)
Atrial Fibrillation/surgery , Cryosurgery/methods , Pulmonary Veins/surgery , Animals , Atrial Fibrillation/diagnostic imaging , Disease Models, Animal , Dogs , Fluoroscopy , Pulmonary Veins/diagnostic imaging , Tomography, X-Ray Computed
6.
Am J Physiol Lung Cell Mol Physiol ; 294(2): L290-9, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18055841

ABSTRACT

CD38 is involved in normal airway function, IL-13-induced airway hyperresponsiveness (AHR), and is also regulated by tumor necrosis factor (TNF)-alpha in airway smooth muscle (ASM) cells. This study aimed to determine whether TNF-alpha-induced CD38 upregulation in ASM cells contributes to AHR, a hallmark of asthma. We hypothesized that AHR would be attenuated in TNF-alpha-exposed CD38-deficient (CD38KO) mice compared with wild-type (WT) controls. Mice (n = 6-8/group) were intranasally challenged with vehicle control or TNF-alpha (50 ng) once and every other day during 1 or 4 wk. Lung inflammation and AHR, measured by changes in lung resistance after inhaled methacholine, were assessed 24 h following the last challenge. Tracheal rings were incubated with TNF-alpha (50 ng/ml) to assess contractile changes in the ASM. While a single TNF-alpha challenge caused no airway inflammation, both multiple-challenge protocols induced equally significant inflammation in CD38KO and WT mice. A single intranasal TNF-alpha challenge induced AHR in the WT but not in the CD38KO mice, whereas both mice developed AHR after 1 wk of challenges. The AHR was suppressed by extending the challenges for 4 wk in both mice, although to a larger magnitude in the WT than in the CD38KO mice. TNF-alpha increased ASM contractile properties in tracheal rings from WT but not from CD38KO mice. In conclusion, CD38 contributes to TNF-alpha-induced AHR after a brief airway exposure to the cytokine, likely by mediating changes in ASM contractile responses, and is associated with greater AHR remission following chronic airway exposure to TNF-alpha. The mechanisms involved in this remission remain to be determined.


Subject(s)
ADP-ribosyl Cyclase 1/metabolism , Bronchial Hyperreactivity/metabolism , Administration, Intranasal , Airway Resistance/drug effects , Animals , Bronchial Hyperreactivity/chemically induced , Bronchial Hyperreactivity/physiopathology , Bronchoalveolar Lavage Fluid/cytology , Chemokines/metabolism , In Vitro Techniques , Inflammation , Isometric Contraction/drug effects , Methacholine Chloride/pharmacology , Mice , Mice, Inbred C57BL , Mice, Knockout , Pulmonary Alveoli/drug effects , Pulmonary Alveoli/pathology , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacology , Trachea/drug effects , Trachea/physiology , Tumor Necrosis Factor-alpha/administration & dosage , Tumor Necrosis Factor-alpha/pharmacology
7.
Am J Physiol Lung Cell Mol Physiol ; 291(6): L1286-93, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16891391

ABSTRACT

The transmembrane glycoprotein CD38 in airway smooth muscle is the source of cyclic-ADP ribose, an intracellular calcium-releasing molecule, and is subject to regulatory effects of cytokines such as interleukin (IL)-13, a cytokine implicated in asthma. We investigated the role of CD38 in airway hyperresponsiveness using a mouse model of IL-13-induced airway disease. Wild-type (WT) and CD38-deficient (CD38KO) mice were intranasally challenged with 5 microg of IL-13 three times on alternate days under isoflurane anesthesia. Lung resistance (R(L)) in response to inhaled methacholine was measured 24 h after the last challenge in pentobarbital-anesthetized, tracheostomized, and mechanically ventilated mice. Bronchoalveolar cytokines, bronchoalveolar and parenchymal inflammation, and smooth muscle contractility and relaxation using tracheal segments were also evaluated. Changes in methacholine-induced R(L) were significantly greater in the WT than in the CD38KO mice following intranasal IL-13 challenges. Airway reactivity after IL-13 exposure, as measured by the slope of the methacholine dose-response curve, was significantly higher in the WT than in the CD38KO mice. The rate of isometric force generation in tracheal segments (e.g., smooth muscle reactivity) was greater in the WT than in the CD38KO mice following incubation with IL-13. IL-13 treatment reduced isoproterenol-induced relaxations to similar magnitudes in tracheal segments obtained from WT and CD38KO mice. Both WT and CD38KO mice developed significant bronchoalveolar and parenchymal inflammation after IL-13 challenges compared with naïve controls. The results indicate that CD38 contributes to airway hyperresponsiveness in lungs exposed to IL-13 at least partly by increasing airway smooth muscle reactivity to contractile agonists.


Subject(s)
ADP-ribosyl Cyclase 1/deficiency , ADP-ribosyl Cyclase 1/genetics , Bronchial Hyperreactivity/physiopathology , Membrane Glycoproteins/deficiency , Membrane Glycoproteins/genetics , Animals , Bronchial Hyperreactivity/genetics , Bronchial Hyperreactivity/prevention & control , Bronchoalveolar Lavage Fluid/cytology , Disease Models, Animal , Interleukin-13/pharmacology , Kinetics , Methacholine Chloride/pharmacology , Mice , Mice, Knockout
SELECTION OF CITATIONS
SEARCH DETAIL
...